1000800-87-2

Usage

Property

Heterocyclic compound
Content: Thiazole ring and pyridine ring

Property

Molecular formula
Content: C9H11N3OS

Property

Molecular weight
Content: 205.27 g/mol

Property

Use in synthesis
Content: Building block in the synthesis of pharmaceuticals and organic molecules

Property

Potential biological activities
Content: Due to its structural features, further research needed to fully understand its potential uses and effects

Upstream product

• 1000801-14-8 3-bromo-6,6-dimethyl-piperidine-2,4-dione 
• 17356-08-0 thiourea 
• 5239-39-4 6,6-dimethylpiperidine-2,4-dione 
• 638-10-8 ethyl 3-methylbut-2-enoate 
• 85532-40-7 Ethyl 3-amino-3-methylbutanoate hydrochloride salt 
• 845267-64-3 ethyl 6,6-dimethyl-2,4-dioxopiperidine-3-carboxylate 
• 845267-63-2 ethyl 3-[(3-ethoxy-3-oxopropanoyl)amino]-3-methylbutanoate 

Downstream Products

• 1000793-42-9 2-(6-bromo-2,3-dihydrobenzo[b][1,4]oxazin-4-yl)-6,7-dihydro-6,6-dimethylthiazolo[5,4-c]pyridin-4(5H)-one 

Relevant academic research and scientific papers

PI3 KINASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN

The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.

Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines

The SAR and pharmacokinetic profiles of a series of multi-isoform PI3K inhibitors based on a 3,4-dihydro-2H-benzo[1,4]oxazine scaffold are disclosed.